We Are Patient Focused 

Here at Ardelyx®, we are dedicated to improving the lives of patients by discovering, developing and commercializing first-in-class targeted therapies that advance patient care. Using our discovery model, Ardelyx scientists identified new biological mechanisms and pathways that enabled us to develop drug candidates designed to address significant unmet medical needs with the goal of improving outcomes for patients.

Ardelyx is publicly traded on the Nasdaq Global Market under the symbol ARDX

Our Partners

Our global partners currently include Kyowa Kirin, Fosun Pharma, and Knight.

  • In November 2017, we executed a license agreement with Kyowa Kirin Co. Ltd., for the development and commercialization of tenapanor for cardiorenal diseases and conditions associated with them, including hyperphosphatemia, in Japan.
  • In December 2017, we executed a license agreement with Shanghai Fosun Pharmaceutical Industrial Development Company Limited for the development and commercialization of tenapanor for irritable bowel syndrome with constipation (IBS-C) and hyperphosphatemia related to chronic kidney disease in China.
  • In March 2018, we executed a license agreement with Knight Therapeutics, Inc. to commercialize tenapanor in Canada for the treatment of IBS-C and hyperphosphatemia. IBSRELA® (tenapanor) is currently available for the treatment of IBS-C in Canada.

Our Commitment to Compliance

At Ardelyx, we foster a culture of compliance and hold our employees, contractors, and other representatives acting on our behalf to a high standard of business and professional conduct. Our core values—passionate, fearless, dedicated, inclusive—guide how we treat each other, our customers, and our patients.

Our Core Values

Passionate

With integrity and determination, we make a difference for patients.

Fearless

By challenging convention, we truly innovate.

Dedicated

Working tirelessly together, we are greater than the sum of our parts.

Inclusive

With respect, grace and humor, we are family.

Management Team

Mike Raab

President &
Chief Executive Officer

Robert Blanks, MS RAC

Chief Regulatory Affairs &
Quality Assurance Officer

Elizabeth Grammer, Esq.

Chief Legal &
Administrative Officer

David Rosenbaum, PhD

Chief Development Officer

j-renz-new

Justin Renz

Chief Financial Officer

Susan Rodriguez

Chief Commercial Officer

Laura Williams, MD MPH

Chief Medical Officer 

Board of Directors

David Mott

Chairman

Geoffrey A. Block, MD

Director

Mike Raab

Director

Robert Bazemore

Director

Onaiza Cadoret-Manier

Director

Muna Bhanji, R.Ph

Director

William A. Bertrand, Jr., JD

Director

Jan M. Lundberg, PhD

Director

Richard Rodgers

Director

Kidney Disease Scientific Advisory Board

Geoffrey A. Block, MD

Kevin J. Martin, MB, BCh, BAO

Glenn M. Chertow, MD, MPH

Sharon M. Moe, MD

Stuart M. Sprague, DO

Derek Forfang

Rory C. Pace, MPH, RD, CSR, FAND

Francesca Tentori, MD, MS

Kam Kalantar-Zadeh, MD, MPH, PhD

Pablo E. Pergola, MD, PhD

Logo Alt

Our Logo

The Ardelyx “A” – Since our founding in 2007, we have been focused on translating our deep understanding of biological mechanisms of ion transport into life-changing medicines. Our stylized “A” visually represents the promise of therapeutics when they interact with specific biological targets. While our logo has evolved over time, we have maintained our unique “A” to recognize our lasting commitment to scientific discovery for the benefit of patients.